Navegando por Autor "Monte, Natasha"
Agora exibindo 1 - 2 de 2
- Resultados por página
- Opções de Ordenação
Artigo Epidemiological-molecular profile of variants associated with type 2 diabetes mellitus in indigenous populations from the Brazilian Amazon(Elsevier BV, 2023-03) Monte, Natasha; Rodrigues, Juliana Carla Gomes; Vinagre, Lui Wallacy Morikawa Souza; Pastana, Lucas Favacho; Alcântara, Angélica Leite de; Leitão, Luciana Pereira Colares; Santos, André Maurício Ribeiro dos; Fernandes, Marianne Rodrigues; Santos, Andrea Kely Campos Ribeiro dos; Guerreiro, João Farias; Assumpção, Paulo Pimentel; Santos, Sidney; Souza, Sandro José de; Santos, Ney Pereira Carneiro dosAims: While lifestyle factors are strongly associated with Type 2 diabetes (T2DM), genetic characteristics also play a role. However, much of the research on T2DM genetics focuses on European and Asian populations, leaving underrepresented groups, such as indigenous populations with high diabetes prevalence, understudied. Methods: We characterized the molecular profile of 10 genes involved in T2DM risk through complete exome sequencing of 64 indigenous individuals belonging to 12 different Amazonian ethnic groups. Results: The analysis revealed 157 variants, including four exclusive variants in the indigenous population located in the NOTCH2 and WFS1 genes with a modifier or moderate impact on protein effectiveness. Furthermore, a high impact variant in NOTCH2 was also found. Additionally, the frequency of 10 variants in the indigenous group showed significant differences when compared to other global populations that were evaluated. Conclusion: Our study identified 4 novel variants associated with T2DM in the NOTCH2 and WFS1 genes in the Amazonian indigenous populations we studied. In addition, a variant with a high predicted impact in NOTCH2 was also observed. These findings represent a valuable starting point for conducting further association and functional studies, which could help to improve our understanding of the unique characteristics of this populationArtigo Severe toxicities in amazonian populations and the role of precision medicine in acute lymphoblastic leukemia treatment(Springer Science and Business Media LLC, 2024-11) Leitão, Luciana Pereira Colares; Monte, Natasha; Rodrigues, Juliana Carla Gomes; Freitas, Lilian Marques de; Santos, André Mauricio Ribeiro dos; Santos, Andrea Kely Campos Ribeiro dos; Santos, Sidney; Souza, Sandro José de; Fernandes, Marianne Rodrigues; Santos, Ney Pereira Carneiro dosCorticosteroids, such as prednisone or dexamethasone, constitute integral components of antineoplastic regimens for Acute Lymphoblastic Leukemia (ALL) therapy, albeit accompanied by significant adverse effects. The multifactorial nature of interindividual variability in drug response, encompassing genetic polymorphisms, underscores the complexity of pharmacotherapy outcomes. However, pharmacogenetic investigations hitherto have predominantly focused on cohorts of European and North American descent, thus limiting the generalizability of findings to populations with minimal representation. Indigenous populations in Brazil, particularly those inhabiting the Amazon region, exhibit a distinctive genetic heritage, predominantly characterized by Native American ancestry. These populations frequently manifest suboptimal therapeutic responses and elevated mortality rates following ALL treatment. Therefore, delineating the molecular signatures of genes implicated in the corticosteroid pathway within these indigenous cohorts assumes paramount importance. This study identified novel variants within genes associated with the glucocorticoid pathway in indigenous Amazonian populations and conducted comparative analyses of variant frequencies across diverse global populations. The findings underscore the genetic uniqueness of indigenous groups and highlight the potential impact of genetic factors on adverse responses to ALL treatment. Precision medicine approaches tailored to the genetic peculiarities of indigenous populations emerge as imperative strategies for optimizing therapeutic efficacy and mitigating treatment-related toxicities in these communities